NCT03830411 is a Phase 2 clinical trial of Sintilimab in Nonsquamous Non-Small Cell Lung Cancer, sponsored by Xin-Hua Xu.

Who is sponsoring NCT03830411?

NCT03830411 is sponsored by Xin-Hua Xu.

What drugs are being tested in NCT03830411?

Interventions in NCT03830411: Sintilimab, Docetaxel, Pemetrexed.

What condition does NCT03830411 study?

NCT03830411 studies Nonsquamous Non-Small Cell Lung Cancer.

Is NCT03830411 still recruiting?

NCT03830411 is currently status unknown. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT03830411

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

Status unknown Phase 2 Last updated 8 November 2021

What this trial tests

Phase 2 trial testing Sintilimab in Nonsquamous Non-Small Cell Lung Cancer in 76 participants. Status unknown.

Timeline

13 March 2019

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Xin-Hua Xu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	13 March 2019
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Sintilimab — full drug profile →
Docetaxel (Docetaxel) — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Nonsquamous Non-Small Cell Lung Cancer — all drugs for Nonsquamous Non-Small Cell Lung Cancer →

Sponsor

Xin-Hua Xu — full company profile →

Who can join

Adults 18 to 75, any sex, with Nonsquamous Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of sintilimab compared with docetaxel or pemetrexed as second-line treatment for patients with stage IV nonsquamous non-small cell lung cancer with wild-type EGFR after failure with platinum-containing chemotherapy. Treatment may continue as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.
Pandey P, Khan F, Qari HA, Upadhyay TK, et al · · 2022 · cited 67× · PMID 35337133 · DOI 10.3390/ph15030335
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Qu J, Mei Q, Liu L, Cheng T, et al · · 2021 · cited 62× · PMID 33643442 · DOI 10.1177/1758835921992968
Sintilimab for the treatment of non-small cell lung cancer.
Zhang L, Lin W, Tan F, Li N, et al · · 2022 · cited 29× · PMID 35436956 · DOI 10.1186/s40364-022-00363-7

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other Xin-Hua Xu trials

Trials by the same sponsor.

NCT06467500 — A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monoth · Phase 2 · recruiting
NCT05749042 — A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients · Phase 2 · unknown
NCT06029829 — The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. · Phase 2 · unknown
NCT05792995 — Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes · Phase 2 · completed
NCT04367909 — A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03830411 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xin-Hua Xu
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03830411.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing